1312.HK
Tongfang Kontafarma Holdings Limited [1312.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1312.HK Stock Summary
In the News
1312.HK Financial details
Company Rating
Neutral
Market Cap
184.1M
Income
-19.64M
Revenue
1.47B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
720
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-1.83
Forward P/E
-
PEG
0.22
P/S
0.23
P/B
0.18
P/C
-
P/FCF
-3.74
Quick Ratio
0.28
Current Ratio
1.37
Debt / Equity
0.11
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-73.6%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-11.4%
Revenue Q/Q
-12.14%
EPS Q/Q
-274.29%
-
-
-
-
SMA20
-25%
SMA50
-
SMA100
-25%
Inst Own
-
Inst Trans
-
ROA
-5%
ROE
-10%
ROC
-0.03%
Gross Margin
57%
Oper. Margin
-5%
Profit Margin
-12%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.026-0.059
52W High
-
52W Low
-
RSI
51.08
Rel Volume
0.01
Avg Volume
852.31K
Volume
6K
Perf Week
-2.86%
Perf Month
-8.11%
Perf Quarter
-
Perf Half Y
-2.86%
-
-
-
-
Beta
0.043
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.034
Change
0%
1312.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.27 | 0.18 | 0.17 | 0.16 | 0.15 | |
| Net income per share | 0.01 | 0 | 0 | -0.02 | -0.01 | |
| Operating cash flow per share | 0 | 0.04 | 0.01 | 0 | 0 | |
| Free cash flow per share | -0.01 | 0 | -0.01 | -0.01 | 0 | |
| Cash per share | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Book value per share | 0.25 | 0.22 | 0.21 | 0.2 | 0.19 | |
| Tangible book value per share | 0.19 | 0.09 | 0.1 | 0.08 | 0.14 | |
| Share holders equity per share | 0.25 | 0.22 | 0.21 | 0.2 | 0.19 | |
| Interest debt per share | 0.18 | 0.14 | 0.14 | 0.11 | 0.02 | |
| Market cap | 892.59M | 485.35M | 273.36M | 251.04M | 200.83M | |
| Enterprise value | 1.64B | 1.07B | 834.35M | 719.17M | 457M | |
| P/E ratio | 13.69 | -24.16 | -60.04 | -2.29 | -6.96 | |
| Price to sales ratio | 0.6 | 0.48 | 0.28 | 0.28 | 0.25 | |
| POCF ratio | 34.77 | 2.35 | 3.64 | -115.95 | 0 | |
| PFCF ratio | -13.82 | 18.65 | -5.54 | -4.66 | 0 | |
| P/B Ratio | 0.63 | 0.4 | 0.23 | 0.23 | 0.19 | |
| PTB ratio | 0.63 | 0.4 | 0.23 | 0.23 | 0.19 | |
| EV to sales | 1.11 | 1.06 | 0.87 | 0.8 | 0.56 | |
| Enterprise value over EBITDA | 3.52 | 5.75 | 8.13 | 8.59 | -7.75 | |
| EV to operating cash flow | 63.98 | 5.17 | 11.11 | -332.18 | 0 | |
| EV to free cash flow | -25.43 | 41.14 | -16.92 | -13.36 | 0 | |
| Earnings yield | 0.07 | -0.04 | -0.02 | -0.44 | -0.14 | |
| Free cash flow yield | -0.07 | 0.05 | -0.18 | -0.21 | 0 | |
| Debt to equity | 0.64 | 0.62 | 0.61 | 0.54 | 0.11 | |
| Debt to assets | 0.22 | 0.3 | 0.28 | 0.28 | 0.07 | |
| Net debt to EBITDA | 1.61 | 3.14 | 5.47 | 5.59 | -4.34 | |
| Current ratio | 1.26 | 1.24 | 1.11 | 1.37 | 1.52 | |
| Interest coverage | 2.4 | 1.28 | -1.25 | -2.02 | -10.77 | |
| Income quality | 0.21 | -1.31 | -230.27 | 0.06 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.11 | 0.14 | 0.14 | 0.13 | 0 | |
| Research and developement to revenue | 0.02 | 0.04 | 0.05 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.22 | 0.33 | 0.3 | 0.33 | 0.15 | |
| Capex to operating cash flow | -3.52 | -0.87 | -1.66 | 23.87 | 0 | |
| Capex to revenue | -0.06 | -0.18 | -0.13 | -0.06 | 0 | |
| Capex to depreciation | -0.56 | -1.24 | -0.86 | -0.4 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.26 | 0.13 | 0.06 | 0.3 | 0.15 | |
| ROIC | 0.06 | 1.08 | -0.25 | -0.02 | -0.16 | |
| Return on tangible assets | 0.02 | -0.01 | 0 | -0.08 | -0.02 | |
| Graham Net | -0.1 | -0.11 | -0.12 | -0.09 | -0.05 | |
| Working capital | 418.99M | 150.32M | 78.12M | 184.8M | 197.8M | |
| Tangible asset value | 1.05B | 502.34M | 558.14M | 465.85M | 808.53M | |
| Net current asset value | -69.1M | -405.73M | -440.31M | -274.66M | -83.99M | |
| Invested capital | 0.64 | 0.62 | 0.61 | 0.54 | 0.11 | |
| Average receivables | 1.47B | 1.03B | 417.58M | 395.67M | 367.19M | |
| Average payables | 295.51M | 182.98M | 49.33M | 30.33M | 14.04M | |
| Average inventory | 124.67M | 115.37M | 116M | 120.46M | 105M | |
| Days sales outstanding | 402.65 | 154.95 | 154.48 | 157 | 157.8 | |
| Days payables outstanding | 152.52 | 47.82 | 29.97 | 20.14 | 7.07 | |
| Days of inventory on hand | 63.65 | 82.76 | 98.61 | 105.16 | 104.09 | |
| Receivables turnover | 0.91 | 2.36 | 2.36 | 2.32 | 2.31 | |
| Payables turnover | 2.39 | 7.63 | 12.18 | 18.13 | 51.63 | |
| Inventory turnover | 5.73 | 4.41 | 3.7 | 3.47 | 3.51 | |
| ROE | 0.05 | -0.02 | 0 | -0.1 | -0.03 | |
| Capex per share | -0.02 | -0.03 | -0.02 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.04 | 0.08 | 0.04 | 0.08 | 0 | |
| Net income per share | 0 | 0 | 0 | 0.01 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0.03 | 0.03 | 0.03 | 0.03 | 0 | |
| Book value per share | 0.2 | 0.2 | 0.2 | 0.2 | 0 | |
| Tangible book value per share | 0.11 | 0.08 | 0.11 | 0.11 | 0 | |
| Share holders equity per share | 0.2 | 0.2 | 0.2 | 0.2 | 0 | |
| Interest debt per share | 0.02 | 0.11 | 0 | 0.07 | 0 | |
| Market cap | 239.93M | 251.04M | 306.9M | 217.57M | 0 | |
| Enterprise value | 117.33M | 719.17M | 156.29M | 445.74M | 256.16M | |
| P/E ratio | -3.56 | -6.05 | 3.92 | 1.39 | 0 | |
| Price to sales ratio | 1.08 | 0.57 | 1.43 | 0.51 | 0 | |
| POCF ratio | 0 | 78.97 | 83.83 | -166.21 | 0 | |
| PFCF ratio | 0 | -10.84 | -59.75 | -11.51 | 0 | |
| P/B Ratio | 0.22 | 0.23 | 0.27 | 0.19 | 0 | |
| PTB ratio | 0.22 | 0.23 | 0.27 | 0.19 | 0 | |
| EV to sales | 0.53 | 1.62 | 0.73 | 1.03 | 0.68 | |
| Enterprise value over EBITDA | -3.2 | -80.26 | -22.57 | -25.58 | -6.16 | |
| EV to operating cash flow | 0 | 226.23 | 42.69 | -340.52 | 0 | |
| EV to free cash flow | 0 | -31.04 | -30.43 | -23.58 | 0 | |
| Earnings yield | -0.07 | -0.04 | 0.06 | 0.18 | 0 | |
| Free cash flow yield | 0 | -0.09 | -0.02 | -0.09 | 0 | |
| Debt to equity | 0.09 | 0.54 | 0.01 | 0.34 | 0.11 | |
| Debt to assets | 0.05 | 0.28 | 0.01 | 0.21 | 0.07 | |
| Net debt to EBITDA | 3.34 | -52.24 | 21.75 | -13.1 | -6.16 | |
| Current ratio | 1.37 | 1.37 | 1.81 | 1.81 | 1.52 | |
| Interest coverage | 0 | -5.17 | 0 | -7.83 | -12.92 | |
| Income quality | 0 | -0.09 | 0.19 | -0.03 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.12 | 0.06 | 0.13 | 0.06 | 0 | |
| Research and developement to revenue | 0.05 | 0.05 | 0.03 | 0.03 | 0.02 | |
| Intangibles to total assets | 0.27 | 0.33 | 0.28 | 0.28 | 0.15 | |
| Capex to operating cash flow | 0 | -8.29 | -2.4 | 13.44 | 0 | |
| Capex to revenue | 0 | -0.06 | -0.04 | -0.04 | 0 | |
| Capex to depreciation | 0 | -0.47 | -0.3 | -0.31 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.12 | 0.09 | 0.13 | 0.18 | 0 | |
| ROIC | -0.05 | -0.03 | -0.01 | -0.02 | -0.06 | |
| Return on tangible assets | -0.01 | -0.01 | 0.01 | 0.03 | -0.05 | |
| Graham Net | -0.1 | -0.09 | -0.07 | -0.04 | 0 | |
| Working capital | 184.8M | 184.8M | 305.43M | 305.43M | 197.8M | |
| Tangible asset value | 592.71M | 465.85M | 629.28M | 629.28M | 808.53M | |
| Net current asset value | -274.66M | -274.66M | -2.88M | -2.88M | -83.99M | |
| Invested capital | 0.09 | 0.54 | 0.01 | 0.34 | 0.11 | |
| Average receivables | 300.25M | 319.85M | 245.95M | 222.16M | 0 | |
| Average payables | 24.01M | 21.4M | 15.08M | 8.76M | 0 | |
| Average inventory | 113.06M | 111.74M | 105.75M | 99.77M | 0 | |
| Days sales outstanding | 103.66 | 78.14 | 44.85 | 70.42 | 83.2 | |
| Days payables outstanding | 18.86 | 9.27 | 8.6 | 4.22 | 3.81 | |
| Days of inventory on hand | 98.48 | 48.39 | 97.9 | 48.04 | 56.1 | |
| Receivables turnover | 0.87 | 1.15 | 2.01 | 1.28 | 1.08 | |
| Payables turnover | 4.77 | 9.71 | 10.46 | 21.33 | 23.62 | |
| Inventory turnover | 0.91 | 1.86 | 0.92 | 1.87 | 1.6 | |
| ROE | -0.02 | -0.01 | 0.02 | 0.03 | -0.06 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
1312.HK Frequently Asked Questions
What is Tongfang Kontafarma Holdings Limited stock symbol ?
Tongfang Kontafarma Holdings Limited is a HK stock and trading under the symbol 1312.HK
What is Tongfang Kontafarma Holdings Limited stock quote today ?
Tongfang Kontafarma Holdings Limited stock price is $0.034 today.
Is Tongfang Kontafarma Holdings Limited stock public?
Yes, Tongfang Kontafarma Holdings Limited is a publicly traded company.
Company Profile
- Volume Average 852.31K
- Market Capitalization 184.1M
- Employee 720
- CEO Mr. Chaowen Jiang
- Headquarters Wan Chai,HK
- IPO Date 2012-01-18
-
Website
https://www.tfkf.com.hk 
Tongfang Kontafarma Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs and laboratory related products in Mainland China, Singapore, Taiwan, and the United States. The company operates in Pharmaceutical Business and Fitness Business segments. It also offers chemical drugs and prescribed traditional Chinese medicines; operates fitness centers; operates in the franchise business; and provides consultation services for fitness and health activities. The company trades in laboratory related products; researches and develops medical products; and offers corporate advisory services. As of December 31, 2021, it operated 12 fitness centers and 2 yoga center in Taiwan; and 10 fitness centers in Singapore. The company was formerly known as Allied Cement Holdings Limited and changed its name to Tongfang Kontafarma Holdings Limited in August 2016. The company was founded in 1993 and is headquartered in Wan Chai, Hong Kong. Tongfang Kontafarma Holdings Limited is a subsidiary of China Health Management Investment Limited.
